IDCRC Newsletter: July 2022IDCRC Profile: Flor M. Munoz, MD, MSc Associate Professor of Pediatrics, Molecular Virology and Microbiology at Baylor College of Medicine and Medical Director, Transplant Infectious Diseases at Texas Children's Hospital
NewsMentoring and Training Key Function Committee Chair to Step Down The IDCRC thanks Kathy Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Chair in Pediatrics at Vanderbilt University, as she steps down as the inaugural co-chair of the IDCRC Mentoring and Training Key Function Committee and for years of service supporting the IDCRC and our mentees. She was pivotal in standing up the Mentoring and Training Key Function Committee and is a great mentor by every standard. Lara A. Danziger-Isakov, MD, MPH to co-chair Mentoring and Training Key Function Committee Dr. Danziger-Isakov is a professor in the Department of Pediatrics at the University of Cincinnati and the director of the Immunocompromised Host Infectious Disease Service at Cincinnati Children’s. She has served as a member of the Mentoring & Training Key Function Committee (KFC) since its inception. She specializes in treating infections for a variety of patient populations, including those who have received solid organ transplants and hematopoietic stem cell transplants, immunocompromised patients and patients undergoing treatment for various cancers. IDCRC study finds rapid decline in vaccine-boosted neutralizing antibodies against Omicron variant BA.5 Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within three months, according to new clinical trial data. The findings, published today in Cell Reports Medicine, are from an ongoing study led by the Infectious Diseases Clinical Research Consortium (IDCRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID is sponsoring the trial. Statement from NIH and BARDA on the Novavax COVID-19 VaccineThe Centers for Disease Control and Prevention (CDC) has recommended that Novavax’s COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older. The Food and Drug Administration (FDA) previously authorized for emergency use the protein-based vaccine, known as NVX-CoV2373. Several VTEU’s participated in the pivotal trial, with Dr. Karen Kotloff, University of Maryland Center for Vaccine Development PI, served as the national co-lead for the study. U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and OverNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and over. Young children and COVID-19 vaccinesThe Pfizer BioNTech vaccine has been approved for children six months through four years, and the Moderna vaccine for ages six months through five years. Evan Anderson, MD, professor of pediatrics and medicine, and an infectious disease physician at Emory and Children’s Healthcare of Atlanta. Anderson was involved in the clinical trials testing vaccines for children six months to 11 years of age at Emory and Children’s. Click below to read the interview with Anderson who answers questions about the new vaccine approval for children five and under. PublicationsNOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: "Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." TrainingMentee Profile: Jared Frisby, DO, Infectious Diseases Fellow, Saint Louis University Dr. Frisby's research focuses on improving inpatient and outpatient vaccine utilization, improving medical education and antimicrobial stewardship. Job PostingsVisit the IDSA Career Center to browse over 200 ID/HIV Medicine job postings. Funding OpportunitiesNIH Funding Opportunities Specific to COVID-19 Understanding the Clinical History of Bacterial Sexually Transmitted Infections (STI) to Accelerate Diagnostic and Vaccine Development (R01 Clinical Trial Not Allowed) - LOI Due August 12 Partnerships for Development of Vaccines Against Select Enteric Pathogens (R01 Clinical Trial Not Allowed) – LOI Due August 14 Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed) – Due August 30 NIH Director’s Transformative Research Award (R01 - Clinical Trial Optional) – Due September 1 Healthcare Infection Society: Major Research Grant - Due September 1 A Multi-omics Approach to Immune Responses in HIV Vaccination and Intervention (P01 Clinical Trial Not Allowed) – LOI Due September 13 IDCRC StudiesActive Studies
Fully Enrolled Studies
IDCRC Concept Quick StatsICP Status
EWG Assignment
ECP Status
NOTE:
Communication ResourcesPlease submit IDCRC news to epthomp@emory.edu for inclusion in the monthly newsletter and IDCRC.org. |